Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Feinstein Institutes Bioelectronic Medicine Researchers Stimulate Vagus Nerve to Reduce Bleeding in Hemophilia
Hemophilia A, a bleeding disorder that prevents blood from clotting, affects more than 30,000 people […]
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in Lupus Nephritis
Kyverna Therapeutics, a cell therapy company with the mission of engineering a new class of […]
Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for ARCT-810, mRNA Therapeutic Candidate for Ornithine Transcarbamylase Deficiency
Arcturus Therapeutics, a global late-stage clinical messenger RNA medicines company focused on the development of […]
CANbridge Announces Marketing Approval of CAN108 in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
CANbridge Pharmaceuticals, a global biopharmaceutical company, with a foundation in China, committed to the research, […]
GC Biopharma Receives a Business License for the Construction of a Plasma Fractionation Plant and Technology Transfer in Indonesia
GC Biopharma, a South Korean biopharmaceutical company, has announced that it has successfully obtained final […]
Cytovation Raises $8 Million in Series A Extension Financing Round for Clinical Advancement of CyPep-1, a First-in-class Targeted Tumor Membrane Immunotherapy
Cytovation ASA, a clinical-stage immune-oncology company focused on the development of its first-in-class targeted tumor […]
FUJIFILM Cellular Dynamics Introduces First-of-its-Kind Human iPSC-derived Blood-Brain Barrier Isogenic Kit
FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells […]
Landmark Bio Partners With InnDura Therapeutics to Advance Immune Cell Therapy Research
Landmark Bio, a collective endeavor bringing together leaders in industry, academia, and research hospitals to […]
Abilita Bio Changes Name to Abilita Therapeutics and Appoints Joel Edwards as Chief Business Officer
Abilita Bio, a leader in enabling the discovery of membrane protein-targeted therapeutics, announced today the […]
Ariceum Therapeutics Expands Pipeline with Acquisition of Theragnostics
Ariceum Therapeutics, a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more